Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial

Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial

Summary: Background: We report on the safety and immunogenicity of V591, a measles vector-based SARS-CoV-2 vaccine candidate. Methods: In this multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial, healthy adults with no history of COVID-19 disease were assigned to intramuscula...

Full description

Bibliographic Details
Main Authors: Frédéric Vanhoutte, Wen Liu, Richard T. Wiedmann, Liesbeth Haspeslagh, Xin Cao, Keith Boundy, Antonios Aliprantis, Michelle Davila, Jonathan Hartzel, Jianing Li, Mac McGuire, Katrin Ramsauer, Yvonne Tomberger, Roland Tschismarov, Deborah D. Brown, Weifeng Xu, Jeffrey R. Sachs, Kevin Russell, S. Aubrey Stoch, Eseng Lai
Format: Article
Language:English
Published: Elsevier 2022-01-01
Series:EBioMedicine
Subjects:
COVID-19
SARS-CoV-2
Vaccine
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396421006058

Internet

http://www.sciencedirect.com/science/article/pii/S2352396421006058

Similar Items